We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly yesterday introduced a $35 monthly insulin co-pay for patients with or without commercial insurance to ensure they have access to the diabetes drug during the COVID-19 crisis. Read More
Gilead CEO Daniel O’Day announced that the company is ramping up production of its antiviral remdesivir for COVID-19 and hopes to have 500,000 treatment courses by October, and more than 1 million treatment courses by the end of the year. Read More